Viewing Study NCT04974034


Ignite Creation Date: 2025-12-25 @ 2:27 AM
Ignite Modification Date: 2025-12-31 @ 12:09 PM
Study NCT ID: NCT04974034
Status: COMPLETED
Last Update Posted: 2021-07-23
First Post: 2021-07-03
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Movement Disorders Analysis Using a Deep Learning Approach
Sponsor: Hospital Avicenne
Organization:

Study Overview

Official Title: Movement Disorders Analysis Using a Deep Learning Approach
Status: COMPLETED
Status Verified Date: 2021-07
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Bradykinesia is a key parkinsonian feature yet subjectively assessed by the MDS-UPDRS score, making reproducible measurements and follow-up challenging.

In a Movement Disorder Unit, the investigators acquired a large database of videos showing parkinsonian patients performing Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III protocols.

Using a Deep Learning approach on these videos, the investigators aimed to develop a tool to compute an objective score of bradykinesia from the three upper limb tests described in the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III.
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: